You are here

Innovation in medicines

Although there is a great need to allow patients earlier access to new medicines, initiatives such as the Innovation Bill are not the way to go, write Professor Sir Alasdair Breckenridge and Dr Peter Feldschreiber

22 December 2015

There are major changes afoot in the complex world of the regulation of medicines. The regulatory burden on
the innovation and production of new drugs
has galvanised regulatory authorities, the pharmaceutical industry, and governments
into proposing new ways of doing things.

At the extreme end of the spectrum, in the
UK a new Bill has been introduced in parliament to facilitate access to innovative treatments.
The new Bill, submitted by Chris Heaton-Harris
MP under the title Access to Medical Treatments (Innovation) Bill, is intended to provide for a database of innovative medical treatments, and encourage responsible innovation by doctors in relation to the carrying out of medical treatment.

A medical treatment for a condition is 'innovative' if it involves a departure from the existing range of accepted medical treatments
for tha...

Want to read on?

This article is part of our subscription-based access. Please pick one of the options below to continue.

Already registered? Login to access premium content

SUBSCRIBE for one User

Unlimited access to the entire SJ website for a full year for one user.

  • 10 issues a year delivered to you
  • Digital edition of the magazine for one user – sent to your inbox or accessible through the website
  • Access to premium content on the website
  • Access to the fully searchable online archive of Solicitors Journal, Managing Partner and Private Client Adviser, which spans over 13 years
  • Weekly email newsletter with all the latest news, analysis and features
  • Comment on SJ content and contribute to the SJ community online
  • Advanced search feature
  • Online support
  • Access to SJ app compatible with Android and Apple devices – coming soon!
  • 6 special focuses per year
  • Special offers and discounts on Solicitors Journal and IICJ events

Subscribe

CORPORATE SUBSCRIPTION

Your department or entire firm can subscribe to Solicitors Journal online, providing easy access for all who require it. Discount corporate subscription rates apply, based on number of users.

The Corporate IP Licence includes:

  • Digital copy of the magazine sent to individuals’ inboxes and accessible through the website. Solicitors Journal publishes 10 issues per year
  • Unlimited access to premium content on the website based on IP addresses
  • Unlimited access to the fully searchable online archive of Solicitors Journal, Managing Partner and Private Client Adviser, which spans over 13 years
  • Weekly email newsletter with all the latest news, analysis and features
  • Comment on SJ content and contribute to the SJ community online (username required)
  • Unlimited access to SJ app compatible with Android and Apple devices
  • 6 special focuses per year
  • Special offers and discounts on Solicitors Journal and IICJ events

The Corporate IP Licence is tailored to your firm, making it the most cost effective way for the firm to access Solicitors Journal, and enables the firm to remain compliant with copyright and our Terms and Conditions. This gives you the ability to print and circulate articles within the firm.

To enquire about a Corporate IP Licence for your firm, please contact our Subscriptions Manager on emily.beechey@solicitorsjournal.com.